JP Morgan Chase
MCRB icon

JP Morgan Chase’s Seres Therapeutics MCRB Stock Holding History

JP Morgan Chase’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-65
Closed -$1.25K – 7627
2025
Q3 		$1.25K Hold
65
– – ﹤0.01% 6965
2025
Q2 		$722 Hold
65
– – ﹤0.01% 6657
2025
Q1 		$913 Hold
65
– – ﹤0.01% 6639
2024
Q4 		$1.08K Hold
65
– – ﹤0.01% 6717
2024
Q3 		$1.23K Hold
65
– – ﹤0.01% 6696
2024
Q2 		$944 Sell
65
-1,907
-97% -$31.8K ﹤0.01% 6626
2024
Q1 		$30.5K Sell
1,972
-1,329
-40% -$28.7K ﹤0.01% 6112
2023
Q4 		$92.4K Sell
3,301
-3,882
-54% -$102K ﹤0.01% 5774
2023
Q3 		$342K Buy
7,183
+183
+3% +$14K ﹤0.01% 4717
2023
Q2 		$671K Sell
7,000
-24,201
-78% -$2.63M ﹤0.01% 4321
2023
Q1 		$3.54M Buy
31,201
+574
+2% +$62.1K ﹤0.01% 3086
2022
Q4 		$3.43M Sell
30,627
-4,892
-14% -$656K ﹤0.01% 3139
2022
Q3 		$4.56M Sell
35,519
-3,523
-9% -$361K ﹤0.01% 2833
2022
Q2 		$2.68M Buy
39,042
+31,939
+450% +$2.75M ﹤0.01% 3309
2022
Q1 		$1.01M Buy
7,103
+5,310
+296% +$817K ﹤0.01% 4249
2021
Q4 		$300K Sell
1,793
-28,479
-94% -$4.53M ﹤0.01% 5133
2021
Q3 		$4.21M Buy
30,272
+27,048
+839% +$5.29M ﹤0.01% 3176
2021
Q2 		$1.54M Sell
3,224
-3,926
-55% -$1.66M ﹤0.01% 3970
2021
Q1 		$2.94M Sell
7,150
-585
-8% -$269K ﹤0.01% 3412
2020
Q4 		$3.79M Sell
7,735
-1,026
-12% -$601K ﹤0.01% 3028
2020
Q3 		$5.04M Sell
8,761
-36,284
-81% -$12.1M ﹤0.01% 2567
2020
Q2 		$4.29M Sell
45,045
-7,238
-14% -$635K ﹤0.01% 2569
2020
Q1 		$3.73M Buy
52,283
+25,189
+93% +$1.69M ﹤0.01% 2502
2019
Q4 		$1.87M Sell
27,094
-2,498
-8% -$185K ﹤0.01% 3431
2019
Q3 		$2.37M Sell
29,592
-4,022
-12% -$266K ﹤0.01% 3305
2019
Q2 		$1.94M Buy
33,614
+3,322
+11% +$315K ﹤0.01% 3402
2019
Q1 		$4.16M Buy
30,292
+10,352
+52% +$1.26M ﹤0.01% 2733
2018
Q4 		$1.8M Sell
19,940
-1,135
-5% -$159K ﹤0.01% 3352
2018
Q3 		$3.2M Buy
21,075
+1,265
+6% +$205K ﹤0.01% 3106
2018
Q2 		$3.41M Sell
19,810
-1,246
-6% -$204K ﹤0.01% 2989
2018
Q1 		$3.09M Sell
21,056
-5,335
-20% -$1.02M ﹤0.01% 2961
2017
Q4 		$5.35M Buy
26,391
+7,724
+41% +$1.59M ﹤0.01% 2631
2017
Q3 		$6.16M Buy
18,667
+5,324
+40% +$1.46M ﹤0.01% 2396
2017
Q2 		$3.02M Sell
13,343
-5,168
-28% -$1.06M ﹤0.01% 2804
2017
Q1 		$4.17M Buy
18,511
+2,543
+16% +$516K ﹤0.01% 2556
2016
Q4 		$3.16M Buy
15,968
+5,039
+46% +$1.1M ﹤0.01% 2788
2016
Q3 		$2.69M Buy
10,929
+298
+3% +$105K ﹤0.01% 2625
2016
Q2 		$6.18M Buy
10,631
+488
+5% +$286K ﹤0.01% 2146
2016
Q1 		$5.39M Sell
10,143
-4
-0% -$2.09K ﹤0.01% 2171
2015
Q4 		$7.12M Buy
10,147
+6,722
+196% +$4.42M ﹤0.01% 2010
2015
Q3 		$2.03M Buy
3,425
+2,185
+176% +$1.78M ﹤0.01% 2738
2015
Q2 		$1.03M Buy
+1,240
New +$1.08M ﹤0.01% 3269

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

JP Morgan Chase's MCRB Position: Q4 2025 in Review

JP Morgan Chase sold out of Seres Therapeutics (MCRB) in Q4 2025, closing a stake of 65 shares — an estimated $1.25K sold.

JP Morgan Chase first reported a position in MCRB in Q2 2015 and held it in 42 quarters. The position peaked at $7.12M in Q4 2015. 36 funds tracked by Wall St. Rank hold MCRB as of Q4 2025.

  • JP Morgan Chase reported no remaining Seres Therapeutics position as of Q4 2025 after selling out during the quarter.
  • JP Morgan Chase sold 65 Seres Therapeutics shares in Q4 2025, an estimated $1.25K.
  • JP Morgan Chase first reported a position in Seres Therapeutics in Q2 2015 and held it in 42 quarters.
  • JP Morgan Chase's Seres Therapeutics position peaked at $7.12M in Q4 2015.
  • 36 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2025.

Based on JP Morgan Chase's 13F filing for Q4 2025, filed 11 Feb 2026.